Monitor the pace of PoC Capital's sales of the 751,879 shares; the $1,000,000 funding is a positive for cash runway but does not offset the dilution risk. The company's cash position and ability to fund its Phase 3 THIO-104 trial without further dilutive offerings is the key risk.
Price Chart
Executive Summary
MAIA Biotechnology filed an S-3 registration statement to register 751,879 shares of common stock for resale by PoC Capital LLC, received under a Clinical Trial Funding Agreement dated August 29, 2026. The company will not receive any proceeds from the resale, but PoC Capital has agreed to provide $1,000,000 in funding for clinical trial expenses. The filing signals potential overhang of approximately 1.2% of shares outstanding, but the funding agreement provides a $1,0 million cash injection for clinical trial costs.
Key Facts
- S-3 registers 751,879 shares for resale by PoC Capital LLC, received under a Clinical Trial Funding Agreement dated August 29, 2026.
- Company will not receive any proceeds from the resale of shares.
- PoC Capital has agreed to provide $1,000,000 in funding following the date of the prospectus for clinical trial expenses.
- Shares represent approximately 1.2% of the 61,741,946 shares outstanding as of September 25, 2026.
- Closing price on September 22, 2026 was $1.37 per share.
- Company is a clinical-stage biopharmaceutical with no revenue and a going concern warning in its forward-looking statements.
- The filing is a resale registration for a single selling stockholder, not a primary offering for the company.
Financial Impact
Potential overhang of 751,879 shares (~$1.0 million at $1.37/share) from PoC Capital, offset by $1,000,000 in funding from PoC Capital for clinical trial funding.
Risk Factors
- Potential overhang from PoC Capital selling 751,879 shares could pressure the stock price.
- Company has no revenue and a going concern risk; additional capital may be needed beyond the $1,000,000 funding.
- Clinical-stage biotech with no approved products; pipeline execution risk.
- The S-3 is a resale registration, not a primary offering; the company gets no cash from the sale of shares.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-044361 |
| Exhibit: ex107.htm | 0001493152-26-044361 |
| Exhibit: ex5-1.htm | 0001493152-26-044361 |
| Exhibit: ex23-1.htm | 0001493152-26-044361 |
| Document: 0001493152-26-044361-index-headers.html | 0001493152-26-044361 |
| Document: 0001493152-26-044361-index.html | 0001493152-26-044361 |
| Document: 0001493152-26-044361.txt | 0001493152-26-044361 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | EFFECT | $1.18 | awaiting T+60 | — | $1.11 (+5.93%) |
Oct 6, 2026 20d ago | 8-K | $1.19 | awaiting T+60 | — | $1.11 (−6.72%) |
Sep 25, 2026 4w ago | S-3 | $1.18 | awaiting T+60 | — | $1.11 (+5.93%) |
Sep 16, 2026 5w ago | Press Release | $1.40 | awaiting T+60 | — | $1.11 (−20.71%) |
Sep 15, 2026 5w ago | Press Release | $1.34 | awaiting T+60 | — | $1.11 (−17.16%) |
Sep 15, 2026 5w ago | Insider Cluster | $1.34 | awaiting T+60 | — | $1.11 (−17.16%) |
Jun 3, 2026 20w ago | Press Release | $1.43 $1.38 | ▼ −3.50% | ▼ −6.00% | $1.11 (−22.38%) |
Jun 2, 2026 20w ago | Insider Cluster | $1.35 $1.39 | ▲ +2.96% | ▲ +1.85% | $1.11 (−17.78%) |
May 19, 2026 22w ago | DEFA14A | $1.23 $1.34 | ▲ +8.94% | ▲ +2.65% | $1.11 (−9.76%) |
May 14, 2026 23w ago | 8-K | $1.26 $1.38 | ▲ +9.52% | ▲ +5.01% | $1.11 (−11.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers